In a 75-year-old patient with an intramural hematoma who is already on a maximized intravenous esmolol infusion and requires a systolic blood pressure of 90–100 mm Hg, what additional agent can be used?

Add Nicardipine or Clevidipine as Second-Line Agent

For a 75-year-old patient with intramural hematoma already on maximal esmolol infusion, add nicardipine or clevidipine as your second agent to achieve the target systolic blood pressure of 90-100 mm Hg.

Rationale for Dual-Agent Therapy in Acute Aortic Disease

In acute aortic disease including intramural hematoma, the primary goal is to reduce aortic wall stress by controlling both heart rate and blood pressure. The European Society of Cardiology specifically recommends that esmolol can be used together with ultra-short acting vasodilating agents such as nitroprusside or clevidipine for acute aortic disease 1. The 2024 ESC guidelines for aortic diseases reinforce that if beta-blockers alone don't achieve the blood pressure target below 120 mm Hg, intravenous vasodilators such as nitrates or dihydropyridine calcium channel blockers (e.g., nicardipine) can be administered concomitantly 2.

Specific Agent Recommendations

First Choice: Nicardipine

• Dosing: Start at 5 mg/h IV infusion, increase by 2.5 mg/h every 5-15 minutes to maximum 15 mg/h 1, 3, 4
• Onset: 5-15 minutes 1
• Advantages: Predictable dose-response, easily titratable, no cyanide toxicity risk
• Contraindication: Liver failure 1

Alternative: Clevidipine

• Dosing: Start at 1-2 mg/h IV, double every 90 seconds until BP approaches target, then increase by less than double every 5-10 minutes; maximum 32 mg/h 3, 4, 5
• Onset: 2-3 minutes 1
• Advantages: Ultra-short acting (5-15 minute duration), rapid titratability
• Contraindications: Soy/egg allergy, defective lipid metabolism 3, 4
• Maximum duration: 72 hours 3, 4

Why Not Nitroprusside?

While nitroprusside is mentioned in guidelines as an option for acute aortic disease 1, it carries significant risks:

• Cyanide toxicity with prolonged use or high doses (≥4-10 mcg/kg/min for >30 minutes) 3, 4
• Requires arterial line monitoring to prevent "overshoot" hypotension 3, 4
• Less predictable dosing in elderly patients 3

Given these safety concerns and the availability of safer alternatives, nicardipine or clevidipine are preferred second-line agents.

Critical Monitoring Points

• Avoid excessive blood pressure reduction: Your target of SBP 90-100 mm Hg is actually more aggressive than guideline recommendations. The ESC guidelines recommend SBP <120 mm Hg for acute aortic disease 1, 2, while the 2024 ESC aortic guidelines specifically target SBP <120 mm Hg and heart rate ≤60 bpm 2
• Monitor for hypotension: At 75 years old, this patient is at higher risk for hypotension-related complications 3
• Ensure adequate beta-blockade first: Beta-blockers must precede or be given simultaneously with vasodilators to prevent reflex tachycardia, which would increase aortic wall stress 4, 2

Common Pitfall to Avoid

Do not use vasodilators alone without adequate beta-blockade. The reflex tachycardia from vasodilators increases dP/dt (rate of pressure change), which paradoxically increases aortic wall stress and can worsen the intramural hematoma 2. Since your patient is already on maximal esmolol (200 mcg/kg/min per FDA labeling 6), you can safely add a vasodilator.

Practical Implementation

1. Verify esmolol is at maximum dose (200 mcg/kg/min for tachycardia; up to 300 mcg/kg/min may be used for hypertension but safety data limited) 6
2. Start nicardipine at 5 mg/h or clevidipine at 1-2 mg/h
3. Titrate every 5-15 minutes (nicardipine) or every 2-5 minutes (clevidipine) to effect
4. Target SBP 100-120 mm Hg (guideline-recommended range) rather than 90-100 mm Hg to avoid excessive hypotension in this elderly patient
5. Maintain heart rate ≤60 bpm 2